Esophageal squamous cell carcinoma
Information
- Disease name
- Esophageal squamous cell carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05603065 | Active, not recruiting | Phase 4 | Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES) | October 10, 2022 | October 2024 |
| NCT05951127 | Active, not recruiting | N/A | Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC | November 1, 2022 | October 31, 2027 |
| NCT04666090 | Active, not recruiting | Phase 2 | Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma | November 23, 2020 | November 2030 |
| NCT06333665 | Active, not recruiting | PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy | February 20, 2024 | May 20, 2024 | |
| NCT06192212 | Active, not recruiting | PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy | December 13, 2023 | June 1, 2024 | |
| NCT04550260 | Active, not recruiting | Phase 3 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | October 19, 2020 | November 30, 2026 |
| NCT04543617 | Active, not recruiting | Phase 3 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | September 28, 2020 | March 31, 2027 |
| NCT05495152 | Active, not recruiting | Phase 3 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | August 1, 2022 | August 31, 2028 |
| NCT05038813 | Active, not recruiting | Phase 2 | Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC) | March 14, 2022 | September 1, 2024 |
| NCT04506138 | Active, not recruiting | Phase 1/Phase 2 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | August 11, 2020 | December 31, 2025 |
| NCT04389177 | Active, not recruiting | Phase 2 | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | July 8, 2020 | December 31, 2024 |
| NCT06010303 | Active, not recruiting | Phase 2 | A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | November 8, 2023 | September 2025 |
| NCT04929392 | Active, not recruiting | Phase 2 | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer | January 25, 2022 | April 25, 2027 |
| NCT06410677 | Active, not recruiting | Changhai Multimodal Esophageal Cancer Cohort | June 13, 2018 | October 1, 2024 | |
| NCT01688908 | Active, not recruiting | N/A | Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC) | January 1, 2012 | December 31, 2027 |
| NCT02465736 | Active, not recruiting | Phase 3 | Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308) | July 2015 | July 2025 |
| NCT04844385 | Active, not recruiting | Phase 2 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | February 20, 2021 | December 20, 2024 |
| NCT04272034 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | March 26, 2021 | June 20, 2026 |
| NCT04764227 | Active, not recruiting | Phase 2 | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) | May 30, 2020 | March 30, 2027 |
| NCT04242199 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | September 4, 2020 | October 31, 2025 |
| NCT03958890 | Active, not recruiting | Phase 3 | A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | June 19, 2019 | December 30, 2023 |
| NCT03946969 | Active, not recruiting | Phase 2 | Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer | May 9, 2019 | October 31, 2022 |
| NCT03322267 | Active, not recruiting | Phase 2 | Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence | October 27, 2018 | June 30, 2025 |
| NCT02890979 | Completed | N/A | Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease | August 3, 2016 | October 10, 2017 |
| NCT02916511 | Completed | Phase 2 | Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma | September 1, 2016 | July 1, 2023 |
| NCT02964455 | Completed | Phase 1 | Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | November 2016 | May 2020 |
| NCT02976896 | Completed | Phase 2 | Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | August 2016 | December 2022 |
| NCT02976909 | Completed | Phase 2 | Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma | October 2016 | December 2018 |
| NCT03116152 | Completed | Phase 2 | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | May 10, 2017 | October 2, 2019 |
| NCT03160209 | Completed | HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi | July 26, 2017 | December 31, 2022 | |
| NCT03187314 | Completed | Phase 2 | Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer | June 14, 2017 | June 30, 2019 |
| NCT00901173 | Completed | A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya | February 10, 2014 | April 20, 2020 | |
| NCT01258192 | Completed | Phase 2 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients | January 2011 | October 2012 |
| NCT01551589 | Completed | N/A | Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer | March 2012 | July 2017 |
| NCT01591135 | Completed | Phase 3 | A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma | April 2012 | August 2018 |
| NCT01598077 | Completed | Phase 1 | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer | July 2012 | March 2014 |
| NCT01605305 | Completed | Phase 2 | Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer | September 2008 | January 2012 |
| NCT01608022 | Completed | Phase 2 | A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus | July 2012 | October 2015 |
| NCT01807546 | Completed | Phase 2 | Oral Rigosertib for Squamous Cell Carcinoma | March 2013 | April 2016 |
| NCT01822613 | Completed | Phase 1 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | July 26, 2013 | June 3, 2016 |
| NCT01831531 | Completed | Phase 2 | Study of S-1 in Combination With Radiotherapy in Esophageal Cancer | March 2013 | October 2018 |
| NCT01854749 | Completed | Phase 2 | S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study | November 2011 | |
| NCT01973725 | Completed | Phase 2 | Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy | October 2013 | December 2018 |
| NCT02047305 | Completed | N/A | Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia | January 2009 | November 2016 |
| NCT02094105 | Completed | N/A | Endoscopic Screening on Esophageal Cancer | November 1999 | December 2013 |
| NCT02100189 | Completed | N/A | Esophageal Cytology With FISH in Detecting Esophageal Cancer | February 2014 | December 2015 |
| NCT02350517 | Completed | Phase 2 | Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer | January 2015 | December 2022 |
| NCT02399306 | Completed | Phase 3 | Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma | September 2014 | October 2017 |
| NCT02435602 | Completed | N/A | The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers | December 2013 | January 2017 |
| NCT02606916 | Completed | Phase 2 | Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer. | July 2015 | August 2020 |
| NCT02645864 | Completed | Phase 1 | Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma | January 2016 | December 2018 |
| NCT02649361 | Completed | Phase 2 | Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) | January 2016 | July 23, 2018 |
| NCT02658214 | Completed | Phase 1 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | April 28, 2016 | November 14, 2019 |
| NCT02844075 | Completed | Phase 2 | Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) | January 2017 | April 26, 2021 |
| NCT03600831 | Completed | Phase 2/Phase 3 | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma | August 20, 2018 | December 31, 2023 |
| NCT03660449 | Completed | Phase 2 | Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma | October 1, 2017 | July 30, 2022 |
| NCT03748134 | Completed | Phase 3 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | December 24, 2018 | July 29, 2023 |
| NCT03792347 | Completed | Phase 1 | Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus | January 21, 2019 | June 17, 2020 |
| NCT03888092 | Completed | Phase 1/Phase 2 | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | August 18, 2017 | December 13, 2022 |
| NCT03925870 | Completed | Phase 2 | KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | June 21, 2019 | July 4, 2022 |
| NCT03985046 | Completed | Phase 2 | Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC | October 10, 2019 | December 31, 2022 |
| NCT04199832 | Completed | To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy | December 20, 2019 | June 30, 2022 | |
| NCT04225364 | Completed | Phase 2 | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma | January 17, 2020 | January 31, 2021 |
| NCT04380480 | Completed | Phase 2 | Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma | February 1, 2020 | March 15, 2022 |
| NCT04548440 | Completed | Phase 2 | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | August 31, 2020 | December 31, 2022 |
| NCT04568200 | Completed | Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma | June 19, 2020 | January 1, 2024 |
| NCT04609813 | Completed | Esophageal cAncer Screening Trial | January 1, 2021 | June 30, 2022 | |
| NCT04732494 | Completed | Phase 2 | AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | March 31, 2021 | December 26, 2023 |
| NCT04764240 | Completed | Precisely Estimation of the Prognostic Value of Lymph Node in ESCC | January 1, 2003 | December 2018 | |
| NCT04764643 | Completed | N/A | The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy | February 1, 2020 | May 31, 2021 |
| NCT04936399 | Completed | A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom | June 25, 2020 | December 3, 2021 | |
| NCT05302011 | Completed | Phase 2 | Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | June 1, 2020 | June 30, 2023 |
| NCT05557955 | Completed | Identification of Breath Biomarkers in Esophageal Cancer | September 27, 2022 | November 15, 2023 | |
| NCT05604950 | Completed | Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 Years | January 1, 2009 | October 1, 2022 | |
| NCT06184841 | Completed | Phase 1 | HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma | June 18, 2020 | December 1, 2023 |
| NCT06241066 | Completed | The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma | January 1, 2014 | October 31, 2023 | |
| NCT06241079 | Completed | Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma | March 31, 2003 | February 1, 2023 | |
| NCT06429865 | Enrolling by invitation | N/A | Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma | May 2024 | December 2024 |
| NCT06048926 | Enrolling by invitation | N/A | Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma | July 30, 2022 | July 30, 2028 |
| NCT05880082 | Enrolling by invitation | Phase 2 | PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer | April 13, 2023 | December 31, 2024 |
| NCT06303583 | Enrolling by invitation | Phase 1/Phase 2 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma | June 1, 2022 | December 31, 2026 |
| NCT05244798 | Not yet recruiting | Phase 3 | Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | November 1, 2022 | December 31, 2026 |
| NCT02490735 | Not yet recruiting | Phase 2 | CIK in Treating Patients With Esophageal Cancer | August 2015 | August 2042 |
| NCT06388135 | Not yet recruiting | Phase 4 | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | May 1, 2024 | May 2027 |
| NCT06329869 | Not yet recruiting | Phase 2 | Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma | May 2024 | November 2027 |
| NCT05927844 | Not yet recruiting | Phase 1 | XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma | June 2023 | June 2025 |
| NCT05900583 | Not yet recruiting | Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD. | June 1, 2023 | August 31, 2025 | |
| NCT05896787 | Not yet recruiting | Phase 2 | Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) | August 1, 2023 | August 1, 2026 |
| NCT05650216 | Not yet recruiting | Phase 2 | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT） | December 25, 2022 | December 25, 2024 |
| NCT06420908 | Not yet recruiting | N/A | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | May 30, 2024 | May 30, 2027 |
| NCT05594914 | Not yet recruiting | Phase 2 | AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma | October 2022 | December 2025 |
| NCT06178211 | Not yet recruiting | Phase 2 | Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial | December 2023 | November 2026 |
| NCT06152978 | Not yet recruiting | Phase 2 | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma | December 15, 2023 | December 15, 2027 |
| NCT05563766 | Not yet recruiting | Phase 2 | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | July 1, 2024 | June 15, 2029 |
| NCT05561699 | Not yet recruiting | N/A | Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer | September 28, 2022 | December 31, 2024 |
| NCT03273647 | Not yet recruiting | Phase 3 | Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin | December 1, 2017 | December 1, 2024 |
| NCT06446726 | Not yet recruiting | Phase 2 | Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma | June 30, 2024 | December 30, 2026 |
| NCT05552651 | Not yet recruiting | Phase 2 | Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | September 20, 2022 | December 20, 2023 |
| NCT06010212 | Not yet recruiting | Phase 1/Phase 2 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | August 25, 2023 | July 1, 2026 |
| NCT06252974 | Not yet recruiting | Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data | April 25, 2024 | December 31, 2024 | |
| NCT05420480 | Not yet recruiting | N/A | Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy | July 1, 2022 | June 1, 2027 |
| NCT05386056 | Not yet recruiting | Phase 2 | Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma | December 1, 2022 | June 30, 2024 |
| NCT05265962 | Not yet recruiting | Phase 2 | Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | December 1, 2022 | December 31, 2024 |
| NCT05980403 | Recruiting | Prediction of Lymph Node Status in Stage T1 Esophageal Squamous Cell Carcinoma（RENMIN-237） | July 18, 2023 | September 18, 2024 | |
| NCT03964753 | Recruiting | Phase 2 | Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma | April 24, 2019 | December 24, 2026 |
| NCT04009265 | Recruiting | Phase 3 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | August 23, 2019 | July 1, 2027 |
| NCT04121286 | Recruiting | Phase 1 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | June 10, 2020 | December 2023 |
| NCT04138212 | Recruiting | Phase 3 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) | October 22, 2019 | December 21, 2028 |
| NCT04140500 | Recruiting | Phase 1/Phase 2 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | November 11, 2019 | December 31, 2025 |
| NCT06463834 | Recruiting | Phase 2 | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | March 20, 2024 | March 19, 2028 |
| NCT04212598 | Recruiting | Phase 2 | The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer | August 3, 2020 | December 3, 2023 |
| NCT04229459 | Recruiting | Phase 2 | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | December 30, 2019 | June 2027 |
| NCT04290806 | Recruiting | Registry Platform Gastric/Esophageal Cancer (SAPHIR) | December 4, 2019 | December 31, 2024 | |
| NCT04328948 | Recruiting | Phase 3 | A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC | July 1, 2020 | March 31, 2030 |
| NCT06281886 | Recruiting | Phase 2 | Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma | December 1, 2023 | December 1, 2026 |
| NCT04389632 | Recruiting | Phase 1 | A Study of SGN-B6A in Advanced Solid Tumors | June 8, 2020 | October 31, 2028 |
| NCT04435197 | Recruiting | Phase 2 | Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | August 11, 2020 | December 2025 |
| NCT04460352 | Recruiting | Phase 3 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer | November 27, 2020 | December 31, 2031 |
| NCT04510129 | Recruiting | A Multicenter Cancer Biospecimen Collection Study | February 5, 2020 | February 2027 | |
| NCT04519905 | Recruiting | N/A | Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) | January 6, 2020 | December 2027 |
| NCT04522687 | Recruiting | Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer | January 1, 2012 | December 2026 | |
| NCT06304974 | Recruiting | Phase 3 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | March 19, 2024 | May 2026 |
| NCT04584008 | Recruiting | N/A | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics | September 23, 2020 | February 2024 |
| NCT04699994 | Recruiting | Phase 2 | Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel | June 25, 2020 | October 31, 2024 |
| NCT06354530 | Recruiting | Phase 2/Phase 3 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | March 8, 2024 | December 31, 2026 |
| NCT04807673 | Recruiting | Phase 3 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) | December 1, 2021 | May 2028 |
| NCT04868877 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | April 28, 2021 | April 2025 |
| NCT06401447 | Recruiting | N/A | TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma | December 1, 2023 | December 1, 2026 |
| NCT04977453 | Recruiting | Phase 1/Phase 2 | GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors | August 2, 2021 | October 2026 |
| NCT05028231 | Recruiting | Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study | June 5, 2021 | December 31, 2024 | |
| NCT05028725 | Recruiting | N/A | Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma | May 16, 2022 | December 31, 2024 |
| NCT05144698 | Recruiting | Phase 1/Phase 2 | RAPA-201 Therapy of Solid Tumors | August 1, 2021 | December 31, 2024 |
| NCT05170256 | Recruiting | Phase 2 | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients | February 4, 2022 | January 2025 |
| NCT05208762 | Recruiting | Phase 1 | A Study of SGN-PDL1V in Advanced Solid Tumors | October 25, 2022 | December 31, 2026 |
| NCT05252078 | Recruiting | Phase 2 | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | June 2, 2022 | November 2026 |
| NCT05281003 | Recruiting | Phase 2 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004) | February 20, 2023 | September 1, 2026 |
| NCT06408584 | Recruiting | Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab | March 1, 2024 | March 1, 2027 | |
| NCT05319730 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | May 16, 2023 | September 20, 2028 |
| NCT05348668 | Recruiting | Phase 2 | Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer | March 1, 2022 | May 1, 2025 |
| NCT05392413 | Recruiting | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | August 1, 2022 | December 31, 2026 | |
| NCT05394415 | Recruiting | Phase 1/Phase 2 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC | May 1, 2022 | April 30, 2025 |
| NCT05426850 | Recruiting | ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma | June 1, 2021 | December 1, 2024 | |
| NCT05462873 | Recruiting | Phase 1 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | April 4, 2023 | January 9, 2026 |
| NCT05469061 | Recruiting | Phase 2 | Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC | January 1, 2022 | November 1, 2022 |
| NCT05490719 | Recruiting | Phase 2 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | August 1, 2022 | September 2025 |
| NCT05507411 | Recruiting | Phase 2 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC | August 3, 2022 | April 2027 |
| NCT05520619 | Recruiting | Phase 2 | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) | September 15, 2022 | July 31, 2026 |
| NCT05541445 | Recruiting | Phase 1/Phase 2 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | August 1, 2022 | December 1, 2024 |
| NCT05591053 | Recruiting | N/A | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans | April 1, 2023 | January 2025 |
| NCT05596890 | Recruiting | Phase 2 | Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients | November 30, 2022 | September 30, 2025 |
| NCT05626569 | Recruiting | Phase 2 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | December 10, 2022 | January 1, 2026 |
| NCT05633641 | Recruiting | Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma | October 19, 2022 | December 31, 2024 | |
| NCT05636150 | Recruiting | Phase 2 | A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma | March 30, 2022 | August 30, 2024 |
| NCT05659251 | Recruiting | Phase 2 | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | December 1, 2022 | December 31, 2029 |
| NCT05740995 | Recruiting | Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | December 1, 2020 | December 2028 | |
| NCT05775419 | Recruiting | N/A | Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC | June 30, 2021 | June 30, 2028 |
| NCT05833594 | Recruiting | Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma | July 1, 2023 | December 1, 2026 | |
| NCT05902988 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | October 18, 2023 | June 2026 |
| NCT05919030 | Recruiting | Phase 3 | A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | July 1, 2023 | July 1, 2027 |
| NCT05978193 | Recruiting | Phase 2 | Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma | January 1, 2023 | January 1, 2027 |
| NCT06225921 | Recruiting | Phase 1 | Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas | December 29, 2023 | January 15, 2025 |
| NCT05984342 | Recruiting | Phase 1 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | August 2, 2023 | June 30, 2029 |
| NCT05990231 | Recruiting | Phase 2 | Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy | September 1, 2023 | August 1, 2025 |
| NCT06006650 | Recruiting | Phase 2 | Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | August 1, 2022 | December 31, 2031 |
| NCT06020885 | Recruiting | Phase 1 | Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study. | August 1, 2023 | July 31, 2024 |
| NCT06022861 | Recruiting | Phase 3 | A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | October 12, 2023 | December 2026 |
| NCT06034860 | Recruiting | Phase 1 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | November 1, 2023 | October 2026 |
| NCT06047379 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | November 1, 2023 | August 31, 2026 |
| NCT06056336 | Recruiting | Phase 2 | Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma | September 7, 2023 | December 31, 2026 |
| NCT06063941 | Recruiting | N/A | High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy | October 10, 2023 | April 30, 2024 |
| NCT06084481 | Recruiting | Phase 1 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | November 9, 2023 | July 1, 2026 |
| NCT06103890 | Recruiting | Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma | May 22, 2023 | July 31, 2025 | |
| NCT06109207 | Recruiting | Phase 1 | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas | October 31, 2023 | October 31, 2025 |
| NCT06122493 | Recruiting | Phase 2 | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | November 1, 2022 | November 1, 2026 |
| NCT06125262 | Recruiting | Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC. | November 1, 2022 | July 31, 2025 | |
| NCT06165380 | Recruiting | Phase 2 | Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | October 23, 2023 | December 31, 2025 |
| NCT06173986 | Recruiting | Phase 1/Phase 2 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | January 10, 2023 | December 30, 2027 |
| NCT06186609 | Recruiting | Phase 2 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | July 1, 2023 | June 30, 2026 |
| NCT06190639 | Recruiting | Phase 2 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | October 25, 2023 | December 31, 2027 |
| NCT06190782 | Recruiting | Phase 3 | Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor | September 27, 2022 | September 27, 2027 |
| NCT06190847 | Recruiting | Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer | July 1, 2023 | July 1, 2026 | |
| NCT03790553 | Recruiting | Phase 3 | Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma | October 15, 2018 | October 15, 2025 |
| NCT06194734 | Recruiting | Phase 3 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | February 5, 2024 | December 30, 2027 |
| NCT04084158 | Suspended | Phase 2 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. | September 7, 2019 | December 30, 2021 |
| NCT02023541 | Terminated | Phase 1 | Proton Beam Therapy to Treat Esophageal Cancer | January 2014 | April 2015 |
| NCT03251417 | Terminated | Phase 2 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma | September 10, 2017 | April 25, 2021 |
| NCT04032704 | Terminated | Phase 2 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | October 9, 2019 | November 28, 2023 |
| NCT03278626 | Terminated | Phase 1/Phase 2 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | June 27, 2017 | May 31, 2021 |
| NCT03206125 | Terminated | NCI UNC Project ESCC | August 1, 2017 | May 15, 2020 | |
| NCT01740375 | Terminated | Phase 3 | Role of Esophagectomy in Complete Responders to CCRT | November 2012 | January 2017 |
| NCT04244552 | Terminated | Phase 1 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | February 11, 2020 | November 1, 2023 |
| NCT04060342 | Terminated | Phase 1 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | August 13, 2019 | April 11, 2022 |
| NCT05461794 | Terminated | Phase 2 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | October 3, 2022 | February 26, 2024 |
| NCT04390958 | Unknown status | Phase 2 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | May 15, 2020 | December 2022 |
| NCT04115618 | Unknown status | Phase 2 | SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma | January 1, 2017 | December 1, 2021 |
| NCT04440332 | Unknown status | Surveillance of Peripheral Blood of Lymphocyte and Immunocyte in Neoadjuvant Therapy Patients With Esophageal Squamous Cell Carcinoma (pLINE) | July 1, 2020 | December 31, 2022 | |
| NCT03713749 | Unknown status | N/A | Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial | October 22, 2018 | December 22, 2022 |
| NCT04481100 | Unknown status | Phase 2 | CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer | October 1, 2020 | July 31, 2023 |
| NCT04503967 | Unknown status | Phase 2 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer | August 1, 2020 | August 1, 2021 |
| NCT02913066 | Unknown status | Phase 2 | S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma | September 2016 | March 2019 |
| NCT04514822 | Unknown status | N/A | Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCC | March 1, 2019 | December 30, 2023 |
| NCT04514835 | Unknown status | Phase 2 | A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC | December 1, 2021 | January 31, 2023 |
| NCT03922230 | Unknown status | Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer | March 1, 2019 | March 31, 2021 | |
| NCT02677597 | Unknown status | Phase 3 | Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma | January 2016 | January 2019 |
| NCT02915432 | Unknown status | Phase 1/Phase 2 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | December 2016 | April 30, 2022 |
| NCT02665702 | Unknown status | Phase 2 | Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | January 2016 | September 2019 |
| NCT03766178 | Unknown status | Phase 2 | Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | September 2021 | September 2023 |
| NCT03913182 | Unknown status | Phase 2 | Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer | April 2, 2019 | May 30, 2021 |
| NCT04275986 | Unknown status | Phase 2 | Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma | January 20, 2020 | March 2024 |
| NCT04644250 | Unknown status | Phase 2 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | September 1, 2020 | March 1, 2024 |
| NCT02647125 | Unknown status | Phase 2 | A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC | October 2015 | December 2022 |
| NCT04063683 | Unknown status | Phase 2 | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. | October 7, 2019 | June 2022 |
| NCT04721223 | Unknown status | Phase 1/Phase 2 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | April 26, 2021 | October 28, 2022 |
| NCT01398449 | Unknown status | Phase 3 | Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 | April 2011 | December 2017 |
| NCT04759235 | Unknown status | Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC | January 1, 2020 | December 31, 2022 | |
| NCT02586753 | Unknown status | Phase 2 | Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus | December 2015 | September 2016 |
| NCT01402180 | Unknown status | Phase 2/Phase 3 | Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy | December 2010 | December 2015 |
| NCT03185988 | Unknown status | Phase 2 | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | July 1, 2017 | September 2021 |
| NCT04767295 | Unknown status | Phase 2 | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) | March 1, 2021 | March 1, 2023 |
| NCT04813406 | Unknown status | N/A | Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | March 2021 | January 2022 |
| NCT04851132 | Unknown status | N/A | Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma | March 11, 2021 | June 2023 |
| NCT04866381 | Unknown status | Phase 2 | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody | April 2021 | April 2023 |
| NCT03797625 | Unknown status | Phase 2 | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | May 4, 2017 | December 31, 2021 |
| NCT04880811 | Unknown status | Phase 2 | Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification | July 2021 | May 2023 |
| NCT02384811 | Unknown status | Phase 2 | Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma | December 2014 | July 2019 |
| NCT03817567 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | July 17, 2018 | May 31, 2020 |
| NCT04984018 | Unknown status | Phase 2 | Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | December 1, 2021 | December 31, 2023 |
| NCT05007145 | Unknown status | Phase 2 | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | August 15, 2021 | August 31, 2023 |
| NCT04054518 | Unknown status | Phase 2 | Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma | October 1, 2019 | October 1, 2022 |
| NCT04045496 | Unknown status | Phase 1 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | September 26, 2019 | March 2024 |
| NCT02325986 | Unknown status | Phase 2 | Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer | March 2015 | December 2017 |
| NCT05044728 | Unknown status | Phase 2 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | April 1, 2021 | March 31, 2023 |
| NCT03940976 | Unknown status | Phase 2 | Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01) | April 28, 2019 | May 1, 2020 |
| NCT03940001 | Unknown status | Early Phase 1 | A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer | May 1, 2019 | May 1, 2022 |
| NCT05174325 | Unknown status | Phase 2 | Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma | December 1, 2020 | July 1, 2022 |
| NCT05189730 | Unknown status | Phase 2 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC | July 1, 2021 | December 31, 2023 |
| NCT03474341 | Unknown status | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer | April 9, 2018 | January 2022 | |
| NCT05213312 | Unknown status | Phase 2/Phase 3 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | June 1, 2022 | March 1, 2024 |
| NCT04229849 | Unknown status | Phase 2 | Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | January 2020 | January 2022 |
| NCT03817658 | Unknown status | Phase 2 | A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC | October 2019 | October 2021 |
| NCT05287880 | Unknown status | Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC | March 10, 2022 | December 31, 2023 | |
| NCT05199649 | Unknown status | N/A | Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora | December 1, 2021 | June 1, 2023 |
| NCT03833466 | Unknown status | Phase 2 | Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo) | February 5, 2019 | June 20, 2020 |
| NCT03603756 | Unknown status | Phase 2 | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | July 31, 2018 | March 28, 2021 |
| NCT03224221 | Unknown status | Phase 2 | Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | March 23, 2017 | June 23, 2019 |
| NCT03623737 | Unknown status | Phase 2/Phase 3 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | March 1, 2017 | December 1, 2023 |
| NCT04224363 | Unknown status | N/A | Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction | January 2020 | February 2020 |
| NCT01391572 | Unknown status | Phase 2 | A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer | April 2011 | |
| NCT04177797 | Unknown status | Phase 2 | Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | March 20, 2020 | December 31, 2023 |
| NCT04170257 | Unknown status | N/A | Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions | October 18, 2019 | December 31, 2022 |
| NCT03857763 | Unknown status | Phase 2 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma | March 1, 2019 | March 1, 2023 |
| NCT04229537 | Unknown status | Phase 1 | Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC | March 1, 2020 | December 1, 2022 |
| NCT03387904 | Unknown status | Phase 2 | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma | January 13, 2019 | December 1, 2022 |
| NCT03987815 | Unknown status | Phase 2 | Neoadjuvant Nivolumab for Operable Esophageal Carcinoma | August 1, 2019 | July 31, 2022 |
| NCT04229524 | Unknown status | N/A | Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction | June 1, 2020 | December 31, 2021 |
| NCT05317325 | Unknown status | Phase 1 | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | April 1, 2022 | April 1, 2024 |
| NCT03927495 | Unknown status | Phase 2 | KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | May 22, 2019 | December 31, 2021 |
| NCT03377400 | Unknown status | Phase 2 | Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer | December 14, 2017 | December 30, 2021 |
| NCT02272699 | Withdrawn | Phase 2/Phase 3 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | November 2014 | December 2020 |
| NCT05312372 | Withdrawn | Phase 1/Phase 2 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | May 2025 | June 2026 |
| NCT03592407 | Withdrawn | Phase 2 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | July 1, 2018 | April 2020 |
| NCT01498757 | Withdrawn | Genome-wide Association Study | January 2012 | July 3, 2012 |